USPTO serial 98880974
LUMEBLUE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- DUBOIS, SUSAN L
- Law office
- TMO LAW OFFICE 111
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with LUMEBLUE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
John Pickerill
John Pickerill Fredrikson & Byron, P.A.60 South 6th Street, Suite 1500Minneapolis, MN 55402United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations; Medicines for human purposes; Medical reagent; Diagnostic agents, preparations and substances for medical and surgical purposes; Diagnostic agents, preparations and substances for medical purposes, namely, the visual enhancing of polyps, adenomas, carcinomas, early stage cancers and other lesions in the colon for patients undergoing colonoscopy; Diagnostic agents, preparations and substances for medical purposes, namely, the visualization of colonic polyps, adenomas, carcinomas, early stage cancers and other lesions in patients undergoing screening colonoscopy including patients at high risk of colorectal carcinoma (CRC), those with previous history of polyps, adenomas, carcinomas, early stage cancers and other lesions, patients with colorectal cancer and patients with relevant family history; Diagnostic reagents and coloring agent for medical and surgical use; Coloring agent for use with imaging medical equipment; Coloring agent for use with colonoscopic equipment; pharmaceutical preparations for use in gastroenterology; pharmaceutical preparations for the differentiation of the tissues of the intestines and colon and polyps, adenomas, carcinomas, early stage cancers and other lesions thereon; pharmaceutical preparations for use in endoscopic or colonoscopic diagnostic evaluation; pharmaceutical preparations for enhancing visualization of polyps, adenomas, carcinomas, early stage cancers and other lesions during gastrointestinal endoscopic procedures; pharmaceutical preparations for use in gastroenterology for colon and digestive system health and regulation; pharmaceutical preparations for use in endoscopy of the gastrointestinal tract; pharmaceutical preparations and preparations aiding detection, diagnosis, prevention and treatment related to the gastrointestinal field; pharmaceutical preparations and preparations aiding detection, diagnosis, prevention and treatment related to the gastrointestinal endoscopy field; pharmaceutical preparations to aid the detection, diagnosis, prevention and treatment of gastroenterological diseases; pharmaceutical preparations, namely, coloring agent for use in endoscopic procedures; pharmaceutical compositions, namely, coloring agent for use in endoscopy; pharmaceutical preparations for use as reagents for medical use; pharmaceutical preparations, namely, coloring agent for use in endoscopy, colonoscopy, sigmoidoscopy, anoscopy, rectoscopy and proctoscopy; pharmaceutical preparations containing methylene blue for enhancing visualization during endoscopic procedures; pharmaceutical preparations containing dyes for enhancing visualization during endoscopy, colonoscopy, sigmoidoscopy, anoscopy, rectoscopy and proctoscopy; pharmaceutical preparations containing methylene blue coloring agent for pharmaceutical, medical and surgical purposes; pharmaceutical preparations containing coloring agent dye for pharmaceutical, medical and surgical purposes; methylene blue for pharmaceutical, medical, surgical and medical diagnostic purposes; dye for pharmaceutical, medical, surgical and medical diagnostic purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 30, 2025 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Sep 30, 2025 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 27, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2025 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 21, 2025 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 2, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 2, 2024 | NWAP | NEW APPLICATION ENTERED | — |